文献速递神经免疫

活动性继发进展型多发性硬化患者的造血干细胞移植

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
PubMed 文献 · Neurology · 2022-12-21

本研究比较自体造血干细胞移植(AHSCT)与其他抗炎疾病修正治疗(DMT)对活动性继发进展型多发性硬化(SPMS)长期残疾恶化的影响,数据来自意大利骨髓移植研究组和意大利多发性硬化登记。匹配后分析显示,AHSCT组首次确认残疾进展(CDP)时间显著延长(HR=0.50;95%CI=0.31-0.81;p=0.005),5年无CDP比例61.7%,且残疾改善率更高。结论认为AHSCT与残疾进展减慢和残疾改善可能性增高相关。

要点

  • AHSCT组首次CDP时间显著长于其他DMT组(HR=0.50;95%CI=0.31-0.81;p=0.005)。
  • AHSCT组5年无CDP比例为61.7%。
  • 移植后3年维持残疾改善者34.7%,其他DMT组为4.6%(p<0.001)。

核心结论

  • 在活动性SPMS患者中,与标准免疫治疗相比,AHSCT与残疾进展减慢及残疾改善可能性增高相关。
  • 本研究提供III级证据表明,与其他DMT相比,AHSCT延长了至CDP的时间。

研究设计与样本

  • 研究收集意大利骨髓移植研究组和意大利多发性硬化登记处的数据。
  • 纳入标准为在诊断为SPMS后开始治疗的患者。
  • 共纳入79例接受AHSCT治疗的患者和1975例接受其他DMT(β干扰素、硫唑嘌呤、醋酸格拉替雷、米托蒽醌、芬戈莫德、那他珠单抗、甲氨蝶呤、特立氟胺、环磷酰胺、富马酸二甲酯和阿仑单抗)治疗的患者,采用倾向评分和重叠加权方法匹配以减少治疗选择偏倚。

主要发现

  • AHSCT组首次CDP时间显著长于其他DMT组(HR=0.50;95%CI=0.31-0.81;p=0.005),AHSCT组5年无CDP比例为61.7%。
  • 10年EDSS时间趋势:其他DMT组每年增加0.157个EDSS分,AHSCT组每年减少0.013个EDSS分(交互作用p<0.001)。
  • 移植后3年维持残疾改善(EDSS低于基线)的患者比例AHSCT组为34.7%,其他DMT组为4.6%(p<0.001)。

关键数值与推荐

  • 残疾恶化通过扩展残疾状况量表(EDSS)评分6个月确认的残疾进展(CDP)累积比例评估。
  • 首次CDP时间采用比例风险Cox回归模型评估。
  • 纵向EDSS时间趋势采用含时间×治疗组交互作用的线性混合模型评估。
  • 残疾改善的患病率采用改良Kaplan-Meier估计量估算,并通过bootstrap曲线下面积进行组间比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Uncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS. METHODS: We collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed disability progression (CDP) according to the Expanded Disability Status Scale (EDSS) score. Key secondary endpoints were the EDSS time trend after treatment start and the prevalence of disability improvement over time. Time to first CDP was assessed by means of proportional hazard Cox regression models. A linear mixed model with a time × treatment group interaction was used to assess the longitudinal EDSS time trends. Prevalence of improvement was estimated using a modified Kaplan-Meier estimator and compared between groups by bootstrapping the area under the curve. RESULTS: Seventy-nine AHSCT-treated patients and 1975 patients treated with other DMTs (beta interferons, azathioprine, glatiramer-acetate, mitoxantrone, fingolimod, natalizumab, methotrexate, teriflunomide, cyclophosphamide, dimethyl fumarate, and alemtuzumab) were matched to reduce treatment selection bias using propensity score and overlap weighting approaches. Time to first CDP was significantly longer in transplanted patients (hazard ratio [HR] = 0.50; 95% CI = 0.31-0.81; p = 0.005), with 61.7% of transplanted patients free from CPD at 5 years. Accordingly, EDSS time trend over 10 years was higher in patients treated with other DMTs than in AHSCT-treated patients (+0.157 EDSS points per year compared with -0.013 EDSS points per year; interaction p < 0.001). Patients who underwent AHSCT were more likely to experience a sustained disability improvement: 34.7% of patients maintained an improvement (a lower EDSS than baseline) 3 years after transplant vs 4.6% of patients treated by other DMTs (p < 0.001). DISCUSSION: The use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that autologous hematopoietic stem cell transplants prolonged the time to CDP compared with other DMTs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Boffa G, Signori A, Massacesi L, et al. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. Neurology. 2022. PMID: 36543569. doi:10.1212/WNL.0000000000206750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。